As it pivots into a new, smaller fund, life sciences investment firm Versant Ventures is devoting a sizable amount of its biopharma portfolio to deals that in past years VCs have considered anathema, with a prearranged buyer waiting a few years down the road.
Two deals announced this week demonstrate Versant’s willingness to develop drug assets, instead of full-blown companies, with single buyers holding...